Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironmentsShogo Kumagai, Hiroyoshi Nishikawa, Shohei Koyama et al.|Cancer Cell|2022Cited by 828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapiesShogo Kumagai, Hiroyoshi Nishikawa, Yosuke Togashi et al.|Nature Immunology|2020Cited by 810
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Jaffer A. Ajani, Florian Lordick et al.|The Lancet|2023Cited by 701
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y. Janjigian, Hyun Cheol Chung, Akihito Kawazoe et al.|Nature|2021Cited by 687